Long-term results from a phase II study of single agent paclitaxel (Taxol®) in previously platinum treated patients with advanced ovarian cancer: The Nordic experience

This publication has 20 references indexed in Scilit:

• Prognosis of patients with ovarian cancer and borderline tumours diagnosed in Norway between 1954 and 1993
  International Journal of Cancer, 1998
• Topotecan versus paclitaxel for the treatment of recurrent epithelial ovarian cancer.
  Journal of Clinical Oncology, 1997
• Extended phase II study of paclitaxel as a 3-h infusion in patients with ovarian cancer previously treated with platinum
  European Journal Of Cancer, 1997
• Paclitaxel (Taxol) in relapsed and refractory ovarian cancer: the UK and Eire experience
  British Journal of Cancer, 1995
• Paclitaxel (Taxol) in heavily pretreated ovarian cancer: Antitumor activity and complications
  Annals of Oncology, 1994
• Phase II trial of paclitaxel in patients with progressive ovarian carcinoma after platinum-based chemotherapy: a Gynecologic Oncology Group study.
  Journal of Clinical Oncology, 1994
• Paclitaxel (Taxol) treatment for refractory ovarian cancer: Phase II clinical trial
  American Journal of Obstetrics and Gynecology, 1994
• Estimates of the worldwide mortality from eighteen major cancers in 1985. Implications for prevention and projections of future burden
  International Journal of Cancer, 1993
• Paclitaxel for platinum-refractory ovarian cancer: results from the first 1,000 patients registered to National Cancer Institute Treatment Referral Center 9103.
  Journal of Clinical Oncology, 1993
• Long-term survival experience of female patients with genital cancer
  British Journal of Cancer, 1988